Correction to: Connectome-guided resection of deep-seated brain tumors using tubular retractors: matched cohort outcomes and exploratory quantitative tractometry - Takeaways - MDSpire

Correction to: Connectome-guided resection of deep-seated brain tumors using tubular retractors: matched cohort outcomes and exploratory quantitative tractometry

  • By

  • Laura Mittelman

  • Iñigo L. Sistiaga

  • Nitish Seenarine

  • Shoaib A. Syed

  • Harshal Shah

  • John Chen

  • James Duehr

  • Luis O. Vargas

  • Samuel Latzman

  • Justin Silverstein

  • Daniel G. Eichberg

  • Michael Schulder

  • Randy S. D’Amico

  • May 6, 2026

  • 0 min

Share

  • 1

    The article presents an erratum regarding figure mislabeling in a study on deep brain tumor resections.

  • 2

    Figure 1 was incorrectly labeled and should have been displayed as Figure 2, and vice versa.

  • 3

    The correction clarifies that both figure legends were accurate despite the visual material being swapped.

  • 4

    The original research focused on connectome-informed resection techniques using tubular retractors.

  • 5

    The erratum was published in the Journal of Neuro-Oncology, ensuring the integrity of the scientific record.

Original Source(s)

Correction to: Connectome-guided resection of deep-seated brain tumors using tubular retractors: matched cohort outcomes and exploratory quantitative tractometry

  • by Laura Mittelman, Iñigo L. Sistiaga, Nitish Seenarine, Shoaib A. Syed, Harshal Shah, John Chen, James Duehr, Luis O. Vargas, Samuel Latzman, Justin Silverstein, Daniel G. Eichberg, Michael Schulder, Randy S. D’Amico

  • May 6, 2026

Related Content

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma